Loading...
ROCO
4123
Market cap914mUSD
Jul 09, Last price  
38.95TWD
1D
-1.02%
1Q
-2.50%
Jan 2017
-27.09%
IPO
-38.73%
Name

Center Laboratories Inc

Chart & Performance

D1W1MN
ROCO:4123 chart
P/E
3.15
P/S
19.35
EPS
12.37
Div Yield, %
1.86%
Shrs. gr., 5y
3.35%
Rev. gr., 5y
16.16%
Revenues
1.52b
-6.28%
253,578,000299,710,000364,519,000462,221,000569,032,000684,436,000713,740,000741,934,000898,759,0006,792,238,00015,039,831,00019,391,814,00021,648,222,0001,437,674,000717,045,000500,107,000767,722,0001,394,008,0001,617,869,0001,516,190,000
Net income
9.32b
P
15,344,000114,653,00045,461,000138,407,00012,964,00042,556,00099,852,00051,911,000333,262,000421,502,00019,455,000249,998,0006,083,797,000-203,589,0003,786,465,0001,816,180,000-575,621,000-995,421,000-1,103,683,0009,322,825,000
CFO
27m
-93.47%
38,810,00067,712,00044,856,00039,114,000-3,861,00070,113,00016,230,00041,504,000-7,539,000-138,291,0001,155,652,0002,013,704,000617,838,000-286,450,000-269,565,000-358,137,000-189,878,000-963,438,000415,715,00027,164,000
Dividend
Oct 03, 20250.72371 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Center Laboratories, Inc. operates as a Taiwanese pharmaceutical enterprise, with its primary focus lying in the manufacturing and distribution of various medical products across Taiwan. Beyond its core drug operations, the firm is heavily invested in the research and development of both small molecule therapeutics and biologics, including proteins and antibodies. Additionally, its extensive portfolio encompasses pharmaceutical CDMO services, medical devices, nutritional health products, agribiotechnology initiatives, advanced stem cell and immune cell therapies, and even strategic ventures in industry investment funds and venture capital. Founded in 1959, Center Laboratories maintains its headquarters in Taipei, Taiwan.
URL
https://www.centerlab.com.tw/
IPO date
Dec 18, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT